by Biospring | Aug 1, 2022 | Advanced Therapy, Biologics, Biomanufacturing, CDMO, Cell and Gene Therapy, CGT, Drug Development, Life Sciences Technology
For a biotech company, discovering a new therapeutic candidate is a years-long, herculean achievement. A crucial question post-discovery is, can the drug be manufactured at scale? Companies must ensure that they can procure enough of a new therapy for clinical trials... 
by Biospring | Apr 26, 2022 | Advanced Therapy, Cell Therapy, CGT, Gene Therapy, Geoffrey Glass, IPSC, Kiniciti, NCardia
In November 2021, we were pleased to announce our investment in Kiniciti, a Cell & Gene Therapy (“CGT”) aggregator. Later in November, Kiniciti announced its first strategic partnership with Ncardia, a leader in developing stem cell-based solutions for...
